News

CanBas and Takeda, along with Takeda Oncology, have initiated the phase-II clinical trials of CBP501, for the treatment of patients with non-small cell lung cancer (NSCLC). Data from

Essilor has extended its external growth strategy through a number of recent transactions in Europe, North America and the Middle East. The company has acquired all outstanding shares

Mylan has announced that its subsidiary Mylan has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Bicalutamide Tablets, 50mg. Bicalutamide Tablets are the

Hyperion has reached an agreement with FDA (under the Special Protocol Assessment process) for the pivotal phase-III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea

sNDA has granted approval for Astellas’ moderately/severely refractory ulcerative colitis, as additional indication for the immunosuppressant Prograf (tacrolimus hydrate). The company had submitted a sNDA to the Pharmaceuticals

Presidio has selected one of the lead compounds in their hepatitis C virus (HCV) NS5A program to advance toward clinical development. The selected Presidio NS5A inhibitor, PPI-461, exhibits

iMedicor has collaborated with Medical Missions for Children (MMC) to distribute their Global Video Library of Medicine worldwide, using streaming video via internet. A final agreement between the

Synergy Pharmaceuticals has completed the final tranche of its private placement. It raised gross proceeds of an aggregate $7.09 million through the sale of 10,132,143 shares of common

Rexahn, a clinical stage biopharmaceutical company developing oncology and CNS therapeutics, has completed patient enrollment in its phase-IIa clinical trial. The study is to evaluate the effectiveness of